The insider selling cluster is too small relative to market cap to warrant a directional signal. Monitor for any upcoming earnings or pipeline catalysts that could explain the timing, but the sales are likely routine portfolio diversification or tax-related. No immediate trading action is indicated.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 9 $165.24entry
- T+1 · 5mo ago −2.65%α −1.07% · $160.86
- T+5 · 5mo ago −3.47%α −5.88% · $159.51
- T+20 · 4mo ago +7.41%α +5.97% · $177.49
- T+60 · 3mo ago −4.51%α −8.32% · $157.79
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Four insiders at Neurocrine Biosciences sold a total of $4.53M in stock over a one-week window, including the Chief Scientific Officer, Chief Human Resources Officer, Chief Regulatory Officer, and a Director. The sales represent approximately 0.028% of the company's $16.4B market cap, which is well below the 0.1% threshold for materiality. The cluster is dominated by C-suite executives, but the dollar amounts are trivial relative to market cap, and no open-market purchases or non-routine patterns are present.
Key Financial Metrics
Key Facts
- Four insiders sold a total of $4.53M in stock over 8 days (May 29, June 5, 2026).
- Sales include the Chief Scientific Officer ($1.76M), Chief Human Resources Officer ($2.20M), Chief Regulatory Officer ($354K), and a Director ($210K).
- Total sales represent ~0.028% of Neurocrine's $16.4B market cap, far below the 0.1% materiality threshold.
- No open-market purchases were reported in the cluster.
- One non-cash gift of 2,441 shares by the Chief Scientific Officer was also filed but has no economic value.
Financial Impact
Total insider sales of $4.53M represent ~0.028% of market cap, immaterial.
Risk Factors
- Insider selling could accelerate if a negative catalyst emerges, but current levels are not predictive.
- No open-market buying to offset the selling, a lack of insider conviction on the buy side.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NBIX-1781040973795 |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers